Indications and achievements of the extension assessment in breast cancer in France

被引：0

作者：

Gaillard, T. ^{[1
]}

Latouche, A. ^{[1
]}

Houzard, S. ^{[2
]}

Rouzier, R. ^{[1
,3
]}

Hequet, D. ^{[1
,3
]}

机构：

[1] Inst Curie, Inserm, U900, 35,Rue Dailly, F-92210 St Cloud, France

[2] Inst Curie, Dept Data, 25,Rue Ulm, F-75005 Paris, France

[3] Inst Curie, Dept Chirurg Oncol, 35,Rue Dailly, F-92210 St Cloud, France

来源：

GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE | 2019年 / 47卷 / 04期

关键词：

SURVIVAL;

D O I：

10.1016/j.gofs.2019.02.005

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

引用

页码：389 / 390

页数：2

共 9 条

[1] Cancer du sein infiltrant non metastatique, 2012, CANC SEIN INF NONM Q
[2] Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
Gobbini, Elisa
Ezzalfani, Monia
Dieras, Veronique
Bachelot, Thomas
Brain, Etienne
Debled, Marc
Jacot, William
Mouret-Reynier, Marie Ange
Goncalves, Anthony
Dalenc, Florence
Patsouris, Anne
Ferrero, Jean Marc
Levy, Christelle
Lorgis, Veronique
Vanlemmens, Laurence
Lefeuvre-Plesse, Claudia
Mathoulin-Pelissier, Simone
Petit, Thierry
Uwer, Lionel
Jouannaud, Christelle
Leheurteur, Marianne
Lacroix-Triki, Magali
Cleaud, Audrey Lardy
Robain, Mathieu
Courtinard, Coralie
Cailliot, Christian
Perol, David
Delaloge, Suzette
[J]. EUROPEAN JOURNAL OF CANCER, 2018, 96 : 17 - 24
[3] NCCN Guidelines® Insights Breast Cancer, Version 1.2017 Featured Updates to the NCCN Guidelines
Gradishar, William J.
Anderson, Benjamin O.
Balassanian, Ron
Blair, Sarah L.
Burstein, Harold J.
Cyr, Amy
Elias, Anthony D.
Farrar, William B.
Forero, Andres
Giordano, Sharon Hermes
Goetz, Matthew P.
Goldstein, Lori J.
Isakoff, Steven J.
Lyons, Janice
Marcom, P. Kelly
Mayer, Ingrid A.
McCormick, Beryl
Moran, Meena S.
O'Regan, Ruth M.
Patel, Sameer A.
Pierce, Lori J.
Reed, Elizabeth C.
Salerno, Kilian E.
Schwartzberg, Lee S.
Sitapati, Amy
Smith, Karen Lisa
Smith, Mary Lou
Soliman, Hatem
Somlo, George
Telli, Melinda
Ward, John H.
Shead, Dorothy A.
Kumar, Rashmi
[J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (04): : 433 - +
[4] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
Hortobagyi, G. N.
Stemmer, S. M.
Burris, H. A.
Yap, Y. S.
Sonke, C. S.
Paluch-Shimon, S.
Campone, M.
Petrakova, K.
Blackwell, K. L.
Winer, E. P.
Janni, W.
Verma, S.
Conte, P.
Arteaga, C. L.
Cameron, D. A.
Mondal, S.
Su, F.
Miller, M.
Elmeliegy, M.
Germa, C.
O'Shaughnessy, J.
[J]. ANNALS OF ONCOLOGY, 2018, 29 (07) : 1541 - 1547
[5] Jehannin-Ligier K., 2017, PROJECTION INCIDENCE
[6] De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype
Press, David J.
Miller, Megan E.
Liederbach, Erik
Yao, Katherine
Huo, Dezheng
[J]. CLINICAL & EXPERIMENTAL METASTASIS, 2017, 34 (08) : 457 - 465
[7] Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
Senkus, E.
Kyriakides, S.
Ohno, S.
Penault-Llorca, F.
Poortmans, P.
Rutgers, E.
Zackrisson, S.
Cardoso, F.
[J]. ANNALS OF ONCOLOGY, 2015, 26 : V8 - V30
[8] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, Sandra M.
Baselga, Jose
Kim, Sung-Bae
Ro, Jungsil
Semiglazov, Vladimir
Campone, Mario
Ciruelos, Eva
Ferrero, Jean-Marc
Schneeweiss, Andreas
Heeson, Sarah
Clark, Emma
Ross, Graham
Benyunes, Mark C.
Cortes, Javier
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08) : 724 - 734
[9] Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population
Tao, Li
Chu, Laura
Wang, Lisa I.
Moy, Lisa
Brammer, Melissa
Song, Chunyan
Green, Marjorie
Kurian, Allison W.
Gomez, Scarlett L.
Clarke, Christina A.
[J]. CANCER CAUSES & CONTROL, 2016, 27 (09) : 1127 - 1138

← 1 →